

# MRC Adjuvant Gastric Infusional Chemotherapy Trial

|                                        |                                                   |                                                                                                   |
|----------------------------------------|---------------------------------------------------|---------------------------------------------------------------------------------------------------|
| <b>Submission date</b><br>06/04/2000   | <b>Recruitment status</b><br>No longer recruiting | <input type="checkbox"/> Prospectively registered<br><input type="checkbox"/> Protocol            |
| <b>Registration date</b><br>06/04/2000 | <b>Overall study status</b><br>Completed          | <input type="checkbox"/> Statistical analysis plan<br><input checked="" type="checkbox"/> Results |
| <b>Last Edited</b><br>28/10/2021       | <b>Condition category</b><br>Cancer               | <input type="checkbox"/> Individual participant data                                              |

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Ms Monica Verma

**Contact details**  
MRC Clinical Trials Unit  
222 Euston Road  
London  
United Kingdom  
NW1 2DA  
-  
not@provided.com

## Additional identifiers

**Protocol serial number**  
ST02

## Study information

**Scientific Title**  
MRC Adjuvant Gastric Infusional Chemotherapy Trial

**Acronym**

MAGIC

**Study objectives**

To investigate whether peri-operative chemotherapy prolongs survival

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Primary study design**

Interventional

**Study design**

Two armed, randomised controlled trial

**Study type(s)**

Not Specified

**Health condition(s) or problem(s) studied**

Gastrointestinal cancer

**Interventions**

Three cycles of pre- and post-operative ECF (Epirubicin, Cisplatin and 5-Fluorouracil) chemotherapy versus surgery alone.

Follow-up: all patients will be followed 6 monthly to 2 years then annually until death.

**Intervention Type**

Drug

**Phase**

Phase III

**Drug/device/biological/vaccine name(s)**

Chemotherapy

**Primary outcome(s)**

1. Survival time
2. Disease-free survival
3. Quality of life
4. Tumour response

**Key secondary outcome(s)**

Not provided at time of registration

**Completion date**

31/12/2001

**Eligibility**

**Key inclusion criteria**

1. Histologically proven adenocarcinoma (Stage II or greater) of the lower third oesophagus or stomach, that is considered to be non-urgently resectable with no evidence of distant metastasis
2. Suitable and fit for cytotoxic chemotherapy
3. WHO performance status of 0 or 1

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Not Specified

**Sex**

Not Specified

**Key exclusion criteria**

1. Other malignant disease other than non-melanomatous skin cancer or in situ carcinoma of the cervix;
2. previous cytotoxic chemotherapy or radiotherapy

**Date of first enrolment**

20/06/1994

**Date of final enrolment**

31/12/2001

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre**

**MRC Clinical Trials Unit**

London

United Kingdom

NW1 2DA

**Sponsor information****Organisation**

Medical Research Council (MRC) (UK)

## Funder(s)

### Funder type

Research council

### Funder Name

Medical Research Council (UK)

### Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

### Funding Body Type

Government organisation

### Funding Body Subtype

National government

### Location

United Kingdom

## Results and Publications

### Individual participant data (IPD) sharing plan

Not provided at time of registration

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

| Output type                           | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---------------------------------------|---------|--------------|------------|----------------|-----------------|
| <a href="#">Results article</a>       | Results | 06/07/2006   |            | Yes            | No              |
| <a href="#">Plain English results</a> |         |              | 28/10/2021 | No             | Yes             |